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Background: Outcome in ST-segment elevation myocardial infarction (STEMI) is affected by
patency of the infarct-related artery (IRA) on the initial angiogram. There is a controversy if
preloading with antiplatelet drugs affects initial IRA patency in case of shortening
transportation time for primary percutaneous coronary intervention (PCI). The aim of
the study was to assess the relation between IRA patency and platelet reactivity on
admission after preloading with aspirin and clopidogrel within 2 h to primary PCI.
Methods: The study included 49 subjects who received 600mg of clopidogrel and 300mg of
aspirin and underwent primary PCI within 120min from loading. Platelet reactivity testing was
performed on admission with means of impedance aggregometry after induction with
arachidonic acid (ASPItest) and adenosine diphosphate with prostaglandin E1 (ADPtest HS) to
assess response to aspirin and clopidogrel, respectively. IRA patency was defined as TIMI flow 2
or 3 on the initial angiogram.
Results: Patent IRA on the initial angiogram was found in 20 patients (41%). Median time
between preloading with antiplatelet drugs and primary PCI was 64min (IQR 59–84min).
Patients who received clopidogrel earlier than 84min before PCI (fourth quartile) had more
suppressed platelet reactivity than patients in the first quartile (o59min) as measured with
ADPtest HS (p¼0.04). Nevertheless, there was no difference in platelet reactivity between
patients with and without IRA patency on the initial angiogram.
Conclusions: In patients preloaded with aspirin and clopidogrel within 2 h to primary PCI, there
was no association between the magnitude of platelet inhibition and IRA patency at the time of
the initial coronary angiography.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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The outcome in ST-segment elevation myocardial infarction
(STEMI) is affected by patency of the infarct-related artery
(IRA) on the initial angiogram [1–3]. It has been demonstrated
that patients with initially patent IRA have better perfusion
after primary percutaneous coronary intervention (PCI),
smaller infarct size (IS) and better survival [1–3].
Since the introduction of the pre-hospital treatment with
loading doses of aspirin and clopidogrel there has been a
belief that this strategy influences initial IRA patency [4,5].
However, available reports show conflicting results [6–10].
The systematic review of the published data demonstrated
that initial IRA patency and clinical outcome were improved
in patients who received pretreatment with clopidogrel [6].
On the contrary, recent results of the Swedish Coronary
Angiography and Angioplasty Registry (SCAAR) and of the
randomized CIPAMI trial demonstrated lack of relation
between preloading with clopidogrel and IRA patency at
baseline [7,10]. Two other recent studies on platelet reactivity
revealed that initial IRA patency may be associated with
higher platelet inhibition by aspirin or clopidogrel, respec-
tively [8,9].
It is hypothesized that the role of preloading with anti-
platelet drugs on the initial IRA patency may depend on the
duration of transportation to the hospital, as the onset of
action of clopidogrel after high loading dose of 600 mg is
generally observed no earlier than 2 h from administration of
the drug [11].
Therefore, the aim of the study was to assess the relation
between initial IRA patency and platelet reactivity on admis-
sion after preloading with aspirin and clopidogrel within 2 h
to primary PCI.2. Materials and methods
2.1. Study population
The study group included 49 subjects treated with primary
PCI. All patients received loading doses of 300 mg of aspirin
and 600 mg of clopidogrel in the pre-hospital phase (in the
referring hospital or in the ambulance), which generally
reflected the transportation time to primary PCI. In any case
the time between preloading and start of primary PCI did not
exceed 120 min. Glycoprotein IIb/IIIa inhibitors were used at
the discretion of the operator. They were administered in the
catheterization laboratory after an initial angiogram and
blood sampling for platelet reactivity testing, which did not
influence the results.
STEMI was defined as (1) presence of continuous chest
pain for at least 30 min, (2) ST-segment elevation in two or
more contiguous ECG leads (Z1 mm for the arm leads and
Z2 mm for precordial leads), and (3) presence of coronary
artery occlusion or significant coronary artery stenosis on the
initial angiogram in the territory corresponding with ECG
changes. Each case of STEMI had to be eventually confirmed
with the presence of an elevated troponin I (TnI). Patency ofIRA was based on the TIMI flow classification and defined as
TIMI flow 2 or 3 [12].
Informed consent was obtained from each participating
patient. The local ethics committee approved the study.
2.2. Platelet aggregation
Platelet reactivity testing was performed with means of a
previously validated multiple electrode impedance aggregome-
try (Multiplate analyzer, Roche, Basel, Switzerland) [13,14]. The
instrument measures the change in impedance between two
electrodes as platelets adhere and aggregate in response to a
specific agonist. Platelet aggregation is recorded continuously.
The increase of impedance is transformed to arbitrary aggrega-
tion units and plotted against time (AUmin).
Platelet reactivity testing was performed on admission from
the blood drawn at the time of the initial angiogram. For that
purpose peripheral blood was withdrawn into a polyethylene
tube containing a stabilized direct thrombin inhibitor (TI blood).
Specific agonists were used to detect platelet reactivity depen-
dent on aspirin (arachidonic acid–ASPItest) and clopidogrel
(adenosine diphosphate plus prostaglandin E1–ADP test HS).
2.3. Statistical analysis
All results for categorical variables were expressed as number
and percentage and for continuous variables as mean and
standard deviation (SD) or median and interquartile range
(IQR), depending on the normality of distribution assessed
with the use of a Kolmogorov–Smirnoff test. Platelet aggrega-
tion measured with multiple electrode impedance aggregome-
try and time between preloading with antiplatelet drugs and
primary PCI were not normally distributed and were therefore
presented as median and IQR. Chi-square test or Fisher exact
test were used for comparison of categorical variables, when
appropriate. A student’s t-test or Mann–Whitney test were
applied to compare continuous variables depending on the
normality of distribution. Correlation was assessedwith means
of the Spearman test. All tests were two-sided with the
significance level of po0.05. Statistical analyses were per-
formedwith the MedCalc statistical software 10.0.2.0 (MedCalc,
Mariakerke, Belgium).3. Results
3.1. Time of preloading and platelet reactivity
The median time between preloading with antiplatelet drugs
and primary PCI was 64 min (IQR 59–84 min, range
13–118 min). There was no significant correlation between
time of preloading and platelet reactivity—for ASPItest
rho¼0.139, p¼0.34 and for ADPtest HS rho¼0.214,
p¼0.14. However, patients who received antiplatelet drugs
earlier than 84 min before PCI (4th quartile) had more
suppressed platelet reactivity than patients in the 1st quartile
(o59 min) as measured with ADPtest HS (82 IQR
16–210 AUmin vs. 204 IQR 89–376 AUmin, p¼0.04), but
not with ASPItest (35 IQR 0–126 AUmin vs. 59 IQR
11–209 AUmin, p¼0.26).
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Patent IRA on the initial angiogram was found in 20 patients
(41%). Patients with initially occluded IRA had larger infarct
size measured with means of peak TnT concentration in
comparison to those with initially patent IRA (81.0 ng/ml vs.
11.1 ng/ml, po0.0001) (Table 1). There was also a trend
towards more frequent presence of proximal lesions in
patients with occluded IRA (67% vs. 35%, p¼0.04) (Table 1).
Median time between preloading with antiplatelet drugs and
primary PCI was similar in both subgroups.
3.3. IRA patency and platelet reactivity at baseline
There was no difference in initial platelet reactivity between
patients with and without IRA patency on the initial angio-
gram as measured with the ASPItest (43.5 IQR
17.8–88.6 AUmin vs. 79.0 IQR 0.0–137.3 AUnmin, p¼0.66)
and the ADPtest HS (145.0 IQR 79.6–296.7 AUnmin vs. 176.0
IQR 87.9–231.3 AUnmin, p¼0.94). Data plots for both of the
analyzed groups are presented in Fig. 1(a and b).
According to producers data (available at http://www.
multiplate.net) ASPItest values below the 5th percentile of
the reference range in the untreated, normal population
(o745 AUnmin) were observed in all of the studied patients.
The same criterion for the high-sensitivity ADPtest (o311
AUnmin) was not met by 12 patients (24%).4. Discussion
Initially patent IRA (TIMI flow 2/3) was related to better post-
procedural perfusion, smaller infarct size, higher leftTable 1 – Characteristics of patients with and without infarct-
Parameter
Age (y) (SD)
Male sex (no.) (%)
Hypertension (no.) (%)
Hyperlipidemia (no.) (%)
Diabetes mellitus (no.) (%)
Current cigarette smoking (no.) (%)
Time from the onset of pain to primary PCI
r2 h
42–6 h
46–12 h
Time between preloading with aspirin and clopidogrel and primary PCI
(IQR)
Infarct related artery (no.) (%)
LAD
RCA
Cx
Lesion location in IRA (no.) (%)
Proximal
Mid
Distal
Peak TnI (ng/ml) (IQR)
Cx: circumflex artery, IRA: infarct-related artery, LAD: left anterior descen
concentration of troponin I, RCA: right coronary artery.ventricular ejection fraction, less frequent progression to
heart failure and lower mortality [1–3].
Results of the CLARITY-TIMI 28 trial demonstrated that
pretreatment with clopidogrel leads to a relative 36%
decrease of the IRA occlusion on the initial angiogram [4].
A significant 32% increase in the initial IRA patency in
patients who received pretreatment with clopidogrel was
also observed in the large systematic review performed by
Vlaar et al. [6]. However, recent reports from the randomized
controlled CIPAMI trial comparing a loading dose of 600 mg of
clopidogrel given in the pre-hospital phase vs. clopidogrel
administered only after the diagnostic angiogram in patients
with STEMI demonstrated no increase in the pre-PCI patency
of the infarct vessel [10]. Lack of the effect of clopidogrel on
the IRA patency was also observed in the Swedish registry—
SCAAR [7].
These contradictory results may be explained by differences
in timing of clopidogrel pretreatment as suggested also by the
authors of the CIPAMI trial [10]. In the CLARITY-TIMI 28 trial
patients were undergoing angiography after 48–192 h from the
start of clopidogrel treatment [4]. Currently used treatment
schemes and improvement in transportation led to a situation
when time between aspirin/clopidogrel loading and PCI is
usually shorter than 120min. Such an interval may be too short
to achieve the satisfactory effect of platelet inhibition, subse-
quent thrombus resolution and restoration of flow in the
occluded artery leading to initial IRA patency [11]. However, none
of the above studies analyzed platelet reactivity at baseline to
verify this hypothesis.
Our results demonstrated that platelet reactivity stimulated
with arachidonic acid for the aspirin effect or adenosine dipho-
sphate and prostaglandin E1 for the clopidogrel effect was
similar in patients with and without patent IRA in case ofrelated artery (IRA) patency on the initial angiogram.
Occluded IRA n¼29
(59%)
Patent IRA n¼20
(41%)
p
60.1 (11.2) 61.6 (9.4) 0.86
20 (69) 16 (80) 0.52
18 (62) 11 (65) 0.84
17 (57) 12 (60) 0.84
5 (17) 3 (15) 1.00
15 (52) 9 (45) 0.86
0.84
5 (17) 3 (15)
20 (69) 13 (65)
4 (15) 4 (20)
65 (61–76) 63.5 (54–91) 0.97
0.35
13 (44) 12 (60)
14 (48) 8 (40)
3 (8) 0 (0)
0.04
19 (67) 7 (35)
7 (25) 12 (60)
3 (8) 1 (5)
81.0 (55.8–106.9) 11.1 (3.9–21.9) o0.0001
ding artery, PCI: percutaneous coronary intervention, peak TnI: peak
Fig. 1 – Data plot showing results of the platelet aggregation
stimulated with arachidonic acid (ASPItest) (a), or adenosine
diphosphate and prostaglandin E1 (high-sensitivity
ADPtest) (b), in a subgroup of patients with occluded (n¼20)
and patent infarct-related artery (IRA) (n¼29).
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there is only one study published recently which analyzed the
relationship between platelet reactivity and IRA patency [9]. The
authors of that study demonstrated lower platelet aggregation
on clopidogrel in patients with patent IRA with means of two
aggregation tests. However, only one of these tests (light trans-
mittance aggregometry) is truly validated to assess platelet
function on clopidogrel, and results obtained from that test
showed only a borderline difference between the studied groups
[15]. In the same study [9], as in ours, there was no difference in
platelet aggregation dependent on aspirin between patients with
patent and occluded IRA.
We cannot exclude the possibility that factors other than
platelet reactivity play a more pivotal role in the restoration
of flow in the IRA. These may include the efficacy of
antithrombotic/fibrinolytic mechanisms or location, size
and structure of the thrombus or atherosclerotic plaque.
It should be noted that at the time of PCI around 25% of the
patients did not develop platelet inhibition below the 5th
percentile of the reference ranges proposed for the clopidogrelby the manufacturer of the aggregometer. This fact supports
the need for widespread introduction of new, more potent and
faster acting P2Y12 receptor inhibitors [16,17]. Further studies
are needed to demonstrate whether pre-hospital administra-
tion of these new drugs in the setting of STEMI improves initial
IRA patency in comparison to other antiplatelet dosing regi-
mens. Nevertheless, pre-hospital administration of clopidogrel
might reduce ischemic complications after primary PCI,
despite the lack of influence on initial IRA patency and is
now a common practice in Europe [10].
The results of this study might have been influenced by a
small sample size. This excluded the possibility to perform
further subgroup analyses. We were also unable to analyze
the influence of different antiplatelet drug dosing regimens
on platelet reactivity, which could have further supported the
conclusion. Due to ethical reasons it was, however, impos-
sible to include a control group of patients who did not
receive preloading with antiplatelet drugs. This is justified
by current STEMI guidelines stating that patients undergoing
primary PCI should receive oral antiplatelet drugs as early as
possible before angiography [18]. Finally, as activated clotting
time (ACT) was not routinely measured in this group, we were
unable to assess the role of antithrombotic treatment in the
restoration of IRA patency.5. Conclusions
In patients preloaded with aspirin and clopidogrel within 2 h
to primary PCI, there was no association between the magni-
tude of platelet inhibition and IRA patency at the time of the
initial coronary angiography. Larger confirmatory studies as
well as studies with new, more potent P2Y12 inhibitors are
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